IGHV3-21 gene expression in patients with B-cell chronic lymphocytic leukemia in Ukraine
- PMID: 18004251
IGHV3-21 gene expression in patients with B-cell chronic lymphocytic leukemia in Ukraine
Abstract
THE AIM of the study was to evaluate the frequency of IGHV3-21 gene usage and its clinical significance for patients with B-cell chronic lymphocytic leukemia (CLL) in Ukraine.
Patients and methods: Immunoglobulin variable heavy chain (IGHV) gene repertoire was studied in 189 CLL patients using reverse transcribed polymerase chain reaction and direct sequence of amplified products.
Results: IGHV3-21 gene expression was found in 11 cases (5.8%), and its frequency was intermediate between Scandinavian (11.7%) and Mediterranean CLL (2.9%) cohorts. The most of cases (9 of 11) belonged to subset with heterogeneous HCDR3 (heteroHCDR3 subset), and only 2 cases--to subset with classical short ARDANGMDV motif (homHCDR3 subset). Six IGHV3-21 cases were mutated and 5 cases were unmutated. All unmutated cases (all were from heteroHCDR3 subset) had similarity of their HCDR3s with previously published sequences. The differences in overall (OS), progression-free (PFS) and treatment-free survival (TFS) for IGHV3-21 positive patients in comparison with CLL patients expressing the other IGHV genes were statistically insignificant. These survival parameters were comparable also for CLL patients with mutated IGHV3-21 gene usage and expression the others mutated IGHV genes. But remarkable feature of IGHV3-21 expressing patients was high incidence of solid tumors. They have developed in 4 IGHV3-21 positive cases (36.4%) and in 10 cases with expression of the others IGHV genes (5.6%, p=0.0002). Furthermore, in small group of 6 patients with mutated IGHV3-21 gene expression, 3 patients had solid tumors and one underwent Richter transformation. Unmutated IGHV3-21 gene expressed patients had worse OS and PFS in comparison with CLL patients that expressed the others unmutated IGHV genes.
Conclusion: Presented data are in agreement with the opinion about negative prognostic significance of IGHV3-21 gene expression regardless its mutation status. IGHV3-21 expression was associated with development of secondary solid tumors. Revealed high level of homology in heteroHDR3s subset might suggest about possible antigenic influence also, in addition to homHCDR3 subset that was proposed earlier.
Similar articles
-
IGHV3-21 gene usage is associated with high TCL1 expression in chronic lymphocytic leukemia.Eur J Haematol. 2010 Feb 1;84(2):109-16. doi: 10.1111/j.1600-0609.2009.01369.x. Epub 2009 Nov 3. Eur J Haematol. 2010. PMID: 19889012
-
Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features.Clin Cancer Res. 2010 Jan 15;16(2):620-8. doi: 10.1158/1078-0432.CCR-09-1638. Epub 2010 Jan 12. Clin Cancer Res. 2010. PMID: 20068100
-
IGHV gene insertions and deletions in chronic lymphocytic leukemia: "CLL-biased" deletions in a subset of cases with stereotyped receptors.Eur J Immunol. 2006 Jul;36(7):1963-74. doi: 10.1002/eji.200535751. Eur J Immunol. 2006. PMID: 16783849
-
B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage.Br J Haematol. 2011 Apr;153(1):3-14. doi: 10.1111/j.1365-2141.2010.08440.x. Epub 2011 Feb 8. Br J Haematol. 2011. PMID: 21303354 Review.
-
What is the current evidence for antigen involvement in the development of chronic lymphocytic leukemia?Hematol Oncol. 2006 Mar;24(1):7-13. doi: 10.1002/hon.760. Hematol Oncol. 2006. PMID: 16315334 Review.
Cited by
-
Immunoglobulin heavy chain variable region gene usage and mutational status of the leukemic B cells in Iranian patients with chronic lymphocytic leukemia.Cancer Sci. 2009 Dec;100(12):2346-53. doi: 10.1111/j.1349-7006.2009.01341.x. Epub 2009 Sep 2. Cancer Sci. 2009. PMID: 19824994 Free PMC article.